There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Acurx Pharmaceuticals (ACXP – Research Report), Champions Oncology (CSBR – Research Report) and Electrocore (ECOR – Research Report) with bullish sentiments.
Acurx Pharmaceuticals (ACXP)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Acurx Pharmaceuticals on January 17 and set a price target of $10.00. The company’s shares closed last Monday at $3.79.
According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Acurx Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $12.00, which is a 239.0% upside from current levels. In a report issued on January 17, H.C. Wainwright also maintained a Buy rating on the stock with a $14.00 price target.
See today’s best-performing stocks on TipRanks >>
Champions Oncology (CSBR)
Craig-Hallum analyst Matt Hewitt assigned a Buy rating to Champions Oncology on January 17. The company’s shares closed last Monday at $6.63.
According to TipRanks.com, Hewitt is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Champions Oncology.
Electrocore (ECOR)
Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Electrocore on January 17 and set a price target of $15.00. The company’s shares closed last Monday at $7.15, close to its 52-week high of $7.50.
According to TipRanks.com, Vendetti is a 1-star analyst with an average return of
Currently, the analyst consensus on Electrocore is a Strong Buy with an average price target of $18.83, a 170.2% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACXP:
